Market Overview

Regado Shares Devastated By Safety Review


After Wednesday's close, Regado Biosciences (NASDAQ: RGDO) issued a press release to announce that the Data Safety Monitoring Board (DSMB) has launched an unplanned review of Regado's REGULATE-PCI trial data.

Shares of Regado have plummeted 56 percent Thursday as the street reacts to the new development.

In response to the announcement, Wedbush analysts issued a research note in which they downgraded shares of Regado from Outperform to Underperform and slashed the price target from $10 to $2.

The team at Wedbush says the launch of the DSMB's unplanned analysis implies the "situation is serious."

Latest Ratings for RGDO

Nov 2014MaintainsHold
Aug 2014DowngradesBuyHold
Aug 2014DowngradesBuyHold

View More Analyst Ratings for RGDO
View the Latest Analyst Ratings

Posted-In: WedbushNews Downgrades Price Target Analyst Ratings


Related Articles (RGDO)

View Comments and Join the Discussion!

Latest Ratings

TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

4 Biotech Stocks Worth A Look Ahead Of FDA Approvals

Stocks Hitting 52-Week Lows